TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05887193

Intervention type: DEVICE
Intervention: Biothesiometry
Description: Biothesiometry using Biothesiometer (Bio Medical Instrument Co, Ohio, United States of America), placed on glans penis and second finger of nondominant hand.

Intervention type: DEVICE
Intervention: Biothesiometry
Description: Biothesiometry using Biothesiometer (Bio Medical Instrument Co, Ohio, United States of America), placed on glans penis and second finger of nondominant hand.

Intervention type: DEVICE
Intervention: Biothesiometry
Description: Biothesiometry using Biothesiometer (Bio Medical Instrument Co, Ohio, United States of America), placed on glans penis and second finger of nondominant hand.

Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy
Description: Penile oxygen pressure using TCM5 Flex and tc84 electrode (Radiometer Medical ApS, Brønshøj, Denmark) placed on glans penis.

Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy
Description: Penile oxygen pressure using TCM5 Flex and tc84 electrode (Radiometer Medical ApS, Brønshøj, Denmark) placed on glans penis.

Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy
Description: Penile oxygen pressure using TCM5 Flex and tc84 electrode (Radiometer Medical ApS, Brønshøj, Denmark) placed on glans penis.

Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy
Description: Penile oxygen pressure using TCM5 Flex and tc84 electrode (Radiometer Medical ApS, Brønshøj, Denmark) placed on glans penis.

Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy
Description: Penile oxygen pressure using TCM5 Flex and tc84 electrode (Radiometer Medical ApS, Brønshøj, Denmark) placed on glans penis.

Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy
Description: Penile oxygen pressure using TCM5 Flex and tc84 electrode (Radiometer Medical ApS, Brønshøj, Denmark) placed on glans penis.

Intervention type: DEVICE
Intervention: Cycling on a home trainer
Description: Riding a static bike Wahoo Bike (Wahoo Fitness LLC, Atlanta, Georgia, United States of America) for 3x 10 minutes at 65-85% of each individual subjects maximal heart rate.
Study: NCT05532111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab combined with tacrolimus induction + rituximab maintenance
Description: RT-R group: Rituximab 1 g/time, once in 15 days, × 2 times, combined with tacrolimus, the initial dose is 0.05-0.1 mg/kg/d, 2 times at an interval of 12 hours, orally. Adjust the dose according to the blood concentration (maintain the blood concentration C0 4-8ng/ml). At the end of 24 weeks, tacrolimus was stopped, and rituximab was given 1 g/time × 1 time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab combined with tacrolimus induction + tacrolimus maintenance
Description: RT-T group: Rituximab 1 g/time, once in 15 days, × 2 times, combined with tacrolimus, the initial dose is 0.05-0.1 mg/kg/d, 2 times at an interval of 12 hours, orally. Adjust the dose according to the blood concentration (maintain the blood concentration C0 4-8ng/ml).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid combined with cyclophosphamide induction + maintenance
Description: PC-C group: The initial dose of prednisone/prednisolone was 0.5-1 mg/kg/d (the maximum dose was 70 mg/d), and the dose was gradually reduced after 4-8 weeks, and then stopped within 6-9 months. Cyclophosphamide 750mg/m2 (adjusted according to eGFR and other conditions), once a month, intravenous pulse therapy. CTX maintenance therapy.
Study: NCT05951829

Intervention type: OTHER
Group type: OTHER
Intervention: Action Observation Therapy
Description: Action Observation Therapy Mirror Therapy
Study: NCT05887193

Intervention type: DEVICE
Intervention: Cycling on a home trainer
Description: Riding a static bike Wahoo Bike (Wahoo Fitness LLC, Atlanta, Georgia, United States of America) for 3x 10 minutes at 65-85% of each individual subjects maximal heart rate.
Study: NCT06313606

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fat negative control
Description: Dietary fat-containing meal plan with a specific supplement that should not modify fat metabolism
Study: NCT06010368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: In TXA group (n=75): 1 g from tranexamic acid (kapron®, Amoun, Egypt) shall also be watered down in 10 cc of Saline, and 5 cc shall be injected in each uterine corn before the placenta is separated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: the oxytocin group (n = 75): 5 I.U of oxytocin (syntocinone 5 I.U/1ML NONARTIS-EGYPT) shall be watered down in 10 cc of saline, and 5 cc shall be injected into each uterine corn before the placental separation
Study: NCT06492057

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyostimulation (EMS)
Description: EasymotionSkin body suit for digitally controlled electric impulses via Easymotion-2 software on crew iPad (frequency, impulse rate, duration) are transferred from integrated dry electrodes of the EMS- stimulation suit to activate surface muscle groups of the body (trunk), arms and legs

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myoton
Description: The non-invasive Myoton technology collects data from passive muscle properties (tone and stiffness) obtained from selected anatomical surface muscle groups
Study: NCT06041581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Healthy Using The Internet (SHUTi)
Description: Sleep Healthy Using The Internet (SHUTi) is an empirically supported internet intervention. It uses a fully automated, interactive, multimedia format to deliver six 45-minute sessions, the structure and content of which mirror face-to-face CBT-I. Session content includes sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and relapse prevention. Each session has the same structure: objectives, sleep diary and homework review, new intervention material, homework assignment, and summary. SHUTi is enhanced through interactive features, including personalized goal setting, graphical feedback based on inputted symptoms, animations and illustrations to enhance comprehension, quizzes to test user knowledge, patient vignettes, and video-based expert explanation. Patients also receive tailored sleep recommendations and feedback based on the sleep diary data they enter into the program. We provide basic tablet skills training and tablets with data plans when needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephonic CBT-I
Description: Telephonic CBT-I will be delivered by our insomnia clinical specialist following the highly cited treatment manual by Perlis et al. (2005). Sessions will occur weekly for 30-50 minutes. Telephonic CBT-I will be delivered from a central location - the Insomnia Clinical Specialist's office. Telephonic CBT-I has been shown to be acceptable, feasible, and effective, with effect sizes similar to face-to-face CBT-I.
Study: NCT06041581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-Face CBT-I
Description: Face-to-face CBT-I will be delivered by our insomnia clinical specialist following the highly cited treatment manual by Perlis et al. (2005). Sessions will occur weekly for 30-50 minutes. Face-to-face CBT-I will be delivered at the Insomnia Clinical Specialist's office. CBT-I is the clear first-line treatment for insomnia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control: Sleep Education/Hygiene, Symptom Monitoring, and Usual Primary Care
Description: A designated trial research assistant will have two calls with each AC patient - one 45-minute call on insomnia education and one 45-minute call on sleep hygiene practices. The same research assistant will also call AC patients monthly to assess insomnia symptoms and will notify clinical staff to encourage additional care when indicated. AC patients will receive usual primary care for insomnia. The targeted clinics utilize a team care approach for behavioral health issues, as PCPs are supported by behavioral health clinicians and psychiatrists available for brief counseling and medication management. However, there is no routine screening for insomnia, and behavioral treatment for insomnia is typically limited to sleep hygiene practices.
Study: NCT06547723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MBSR and physiotherapy
Description: In experimental group in the first session, the research program and plans for outcome assessment will be introduced. They will sign the research agreement form and will be interviewed to obtain information about their pain, their medication(s), and demographics. This will be followed by the first 70-80-minute physiotherapy session. During each session, the physiotherapist will administer the Transcutaneous electrical nerve stimulation (TENS), low-level laser therapy (LLLT), and ultrasound therapy to the painful body region. In addition, they will engage in 20 minutes of exercise during each session.~After that, participants will be received their 8 MBSR session with a trained therapist. They will be given their assignments for the week, consisting of the content of that MBSR session.~Finally, three months after the last study session, they will be asked to return to the clinic for the follow-up assessment to complete patient-reported outcome measures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: In control group in the first session, the research program and plans for outcome assessment will be introduced. The participants then will sign the research agreement form and will be interviewed to obtain information about their pain (i.e., duration, location, and course), their medication(s), and demographics. This will be followed by the first 70-80-minute physiotherapy session. During each session, the physiotherapist will administer the Transcutaneous electrical nerve stimulation (TENS), low-level laser therapy (LLLT), and ultrasound therapy to the painful body region. In addition, they will engage in 20 minutes of exercise during each session.
Study: NCT05258318

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DK crush
Description: Double Kissing Crush (DK-Crush) technique in patients with Unprotected Left Main Bifurcation lesions (ULMb).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DR crush
Description: Double Rewire crush technique (DR-Crush) in patients with Unprotected Left Main Bifurcation lesions (ULMb).
Study: NCT00511745

Intervention type: DRUG
Intervention: Rabeprazol
Description: As prescribed
Study: NCT05727267

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEPLISAV B; TherVacB
Description: Administration of the described combinations via the intramuscular route

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEPLISAV B; TherVacB
Description: Administration of the described combinations via the intramuscular route

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEPLISAV B; TherVacB
Description: Administration of the described combinations via the intramuscular route

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TherVacB
Description: Administration of the described combinations via the intramuscular route

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TherVacB
Description: Administration of the described combinations via the intramuscular route

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TherVacB
Description: Administration of the described combinations via the intramuscular route
Study: NCT05887193

Intervention type: DEVICE
Intervention: Cycling on a home trainer
Description: Riding a static bike Wahoo Bike (Wahoo Fitness LLC, Atlanta, Georgia, United States of America) for 3x 10 minutes at 65-85% of each individual subjects maximal heart rate.

Intervention type: DEVICE
Intervention: Cycling on a home trainer
Description: Riding a static bike Wahoo Bike (Wahoo Fitness LLC, Atlanta, Georgia, United States of America) for 3x 10 minutes at 65-85% of each individual subjects maximal heart rate.

Intervention type: DEVICE
Intervention: Bike Fitting
Description: Setting standardized posture of the rider on the bike using Retül technology (Retül, Specialized Bicycle Components Inc., Boulder, Colorado, United States of America)

Intervention type: DEVICE
Intervention: Bike Fitting
Description: Setting standardized posture of the rider on the bike using Retül technology (Retül, Specialized Bicycle Components Inc., Boulder, Colorado, United States of America)

Intervention type: DEVICE
Intervention: Bike Fitting
Description: Setting standardized posture of the rider on the bike using Retül technology (Retül, Specialized Bicycle Components Inc., Boulder, Colorado, United States of America)

Intervention type: DEVICE
Intervention: Bike Fitting
Description: Setting standardized posture of the rider on the bike using Retül technology (Retül, Specialized Bicycle Components Inc., Boulder, Colorado, United States of America)

Intervention type: DEVICE
Intervention: Bike Fitting
Description: Setting standardized posture of the rider on the bike using Retül technology (Retül, Specialized Bicycle Components Inc., Boulder, Colorado, United States of America)
Study: NCT06022315

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: caloric restrction high carbohydrate low fat diet with exercise training program
Description: Subjects will perform 3 sessions/week of brisk walking for four weeks at a heart rate corresponding to 85-90% of the lactate threshold. The duration of exercise sessions will increase from 30 minutes to 45 minutes in week 2 and from 45 minutes to 60 minutes in weeks 3 and 4.~Experimental diets will be calorie-restricted and provide 70% of estimated daily energy requirements. In the high CHO-low FAT diet, carbohydrates, fat, and protein will provide 60%, 25%, and 15% of individually predicted daily energy intake, respectively. Variety (n=7) of daily menus for calorie-restricted high FAT-low CHO diet will be provided and menus for high CHO-low FAT diet on pasta, rice, oats, fruit, and vegetable.During the intervention, participants will be encouraged to avoid alcohol consumption and only the maximum amount of two units will be allowed per week.
Study: NCT05887193

Intervention type: DEVICE
Intervention: Bike Fitting
Description: Setting standardized posture of the rider on the bike using Retül technology (Retül, Specialized Bicycle Components Inc., Boulder, Colorado, United States of America)
Study: NCT06022315

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: caloric restrction high fat low carbohydrate diet with exercise training program
Description: Subjects will perform 3 sessions/week of brisk walking for four weeks at a heart rate corresponding to 85-90% of the lactate threshold.The duration of exercise sessions will increase from 30 minutes to 45 minutes in week 2 and from 45 minutes to 60 minutes in weeks 3 and 4.~Experimental diets will be calorie-restricted and provide 70% of estimated daily energy requirements. In the low CHO-high FAT diet, the proportion of energy provided by CHO, fat, and protein will consist of 25%, 60%, and 15%, respectively. Variety (n=7) of daily menus for calorie-restricted low CHO-high FAT diet will be provided and menus for high FAT-low CHO group will be based on meat, fish, cheese, butter, and nuts.During the intervention, participants will be encouraged to avoid alcohol consumption and only the maximum amount of two units will be allowed per week.
Study: NCT04976010

Intervention type: OTHER
Intervention: No intervention
Description: There will be no intervention in the separate goups, as this is an observational study

Intervention type: OTHER
Intervention: No intervention
Description: There will be no intervention in the separate goups, as this is an observational study

Intervention type: OTHER
Intervention: No intervention
Description: There will be no intervention in the separate goups, as this is an observational study
Study: NCT05823935

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bakay purse string
Description: After developing the bladder flap, Vicryl polyglactin 910 sutures (Ethicon, Inc, Somerville, NJ) will be placed on the line between the cervicovaginal junction and the bladder starting at either 4 to 3 o'clock or 8 to 9 o'clock, as anchor sutures. Paying attention not to get closer than 1 cm to the bladder, the first suture will be passed from 4 o'clock to 3 o'clock and continued circumferentially in a full-thickness purse string fashion through 3, 1, 10, 8, 7, 5 o'clock completing a circle while including both uterosacral ligaments.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cuff closure via vaginal route group
Description: After the uterus will be removed via vaginal route, vaginal cuff ends will be grasped via vaginal approach and sutured continuous locked sutures using Vicryl polyglactin 910 sutures in one layer.
Study: NCT05923801

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: switch to BT electrode position
Description: use of different electrode positions of ECT device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continue with RUL electrode position
Description: use of different electrode positions of ECT device
Study: NCT05891093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib 50mg bid orally for 1 year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1mg, qd orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1mg, qd orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 2.5mg, qd orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5mg, qd orally
Study: NCT06492057

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electromyography (EMG)
Description: As a standard method, surface EMG collects data from nerve impulse-triggered active muscle contractions, pre/postflight only

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI is a clinically standard (non-radiation) imaging method to study structural changes of the human body (organs, muscle, bones, tendons) at the macroscopic level, pre/postflight only

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamometry
Description: Dynamometry is a standard functional and diagnostic method to test muscle strength in sports and rehabilitation. pre/postflight only
Study: NCT05928689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride tablet
Description: Single dose of 40 mg propranolol tablet
Study: NCT05891093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: 25mg, qd orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25mg, qd orally
Study: NCT06257069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tremor Retrainer Smartphone Application
Description: The Tremor Retrainer smartphone application uses the smartphone's built-in accelerometer to calculate a patient's tremor frequency when the smartphone is strapped to the patient's wrist. The application will provide auditory cues to the patient with a treatment frequency at 2/3 the patient's baseline tremor frequency for half a session, then 1/3 the patient's baseline tremor frequency for the second half of the session. Meanwhile, oscillatory movements will be continuously analyzed with frequency calculated and displayed relative to goal frequency, so that the patient receives continuous feedback via a visual dial as to whether they are meeting treatment goals. Intervention will consist of a one-week Tremor Retrainment Protocol.
Study: NCT05891093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 10mg, bid orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 10mg, bid orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toremifene
Description: 60mg, qd orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toremifene
Description: 60mg, qd orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abemaciclib
Description: 150mg/100mg/50mg, bid orally for 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 150mg/100mg/50mg, bid orally for 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRH agonist
Description: Leuprorelin acetate, goserelin acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH agonist
Description: Leuprorelin acetate, goserelin acetate
Study: NCT04880395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention Arm: dolutegravir/lamivudine
Description: 1 pill QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator ARM: TDF/XTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine)
Description: 1 pill of each QD
Study: NCT06439875

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: effect of L-arginine and liposomial vitamin C on pulmonary rehabilitation
Description: Patients with a certified diagnosis of COPD and chronic respiratory failure will be randomized in a 1:1 ratio into the interventional arm or the placebo controller arm. All patients will undergo multidisciplinary intensive pulmonary rehabilitation for 28 days. The patients in the interventional group will receive a twice-daily oral supplementation with either a combination of 1.66 g l-arginine plus 500 mg liposomal vitamin C

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients in this arm will undergo multidisciplinary intensive pulmonary rehabilitation without any dietary supplementation.
Study: NCT05928689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride tablet
Description: Single dose of 40 mg propranolol tablet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Reactivation of misophonia trigger memory

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Reminder
Description: Reactivation of misophonia trigger memory
Study: NCT05206032

Intervention type: OTHER
Intervention: Raman spectroscopy
Description: Blood (serum or plasma) will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.
Study: NCT06577298

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose
Description: 4 doses of VLP-Polio vaccine (0.5ml) at 2, 3, 4 months and 12-18 months of age for infants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose
Description: 4 doses of VLP-Polio vaccine (0.5ml) at 2, 3, 4 months and 12-18 months of age for infants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLP-Polio medium dose
Description: 4 doses of VLP-Polio vaccine (0.5ml) at 2, 3, 4 months and 12-18 months of age for infants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLP-Polio medium dose
Description: 4 doses of VLP-Polio vaccine (0.5ml) at 2, 3, 4 months and 12-18 months of age for infants
Study: NCT05928689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Reactivation of misophonia trigger memory